Toripalimab
- Generic Name
- Toripalimab
- Brand Names
- Loqtorzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1924598-82-2
- Unique Ingredient Identifier
- 8JXN261VVA
- Background
Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
- Indication
⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)
- Conditions
- Interventions
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2023-04-14
- Target Recruit Count
- 57
- Registration Number
- NCT04807140
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Peking University
- Target Recruit Count
- 53
- Registration Number
- NCT04804696
- Locations
- 🇨🇳
Beijing Cancer Hospital / Peking University Cancer Hospital, Beijing, Beijing, China
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT04785196
- Locations
- 🇨🇳
Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Shanghai East Hospital (East Hospital affiliated to Tongji University), Shanghai, China
Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 218
- Registration Number
- NCT04778956
- Locations
- 🇨🇳
The Tenth Affiliated Hospital, Sun Yat-Sen University, Nanchang, Jiangxi, China
🇨🇳The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)
- Conditions
- Interventions
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 341
- Registration Number
- NCT04772287
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2021-02-25
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04771715
- Locations
- 🇨🇳
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Study of LM-061 in Subjects in Advanced Tumors
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 18
- Registration Number
- NCT04737122
- Locations
- 🇦🇺
St George Private Hospital, Kogarah, New South Wales, Australia
Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- Third Military Medical University
- Target Recruit Count
- 80
- Registration Number
- NCT04731909
- Locations
- 🇨🇳
Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China
Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Sichuan Cancer Hospital and Research Institute
- Target Recruit Count
- 27
- Registration Number
- NCT04725448
- Locations
- 🇨🇳
Sichuan Cancer Hospital, Chengdu, Sichuan/China, China
Toripalimab Combined With Chemotherapy in Primary Tracheal Squamous Cell Carcinoma
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 15
- Registration Number
- NCT04716751
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.